DA
CRSP icon

Doliver Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Doliver Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,083
Closed -$201K – 153
2022
Q3 		$201K Sell
3,083
-1,334
-30% -$96.7K 0.07% 137
2022
Q2 		$268K Sell
4,417
-639
-13% -$37.6K 0.1% 131
2022
Q1 		$317K Sell
5,056
-1
-0% -$63 0.1% 128
2021
Q4 		$313K Buy
5,057
+1,301
+35% +$114K 0.1% 124
2021
Q3 		$420K Buy
3,756
+962
+34% +$121K 0.14% 115
2021
Q2 		$452K Sell
2,794
-756
-21% -$91.9K 0.15% 93
2021
Q1 		$433K Buy
+3,550
New +$536K 0.16% 91

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Doliver Advisors's CRSP Position: Q4 2022 in Review

Doliver Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 3,083 shares — an estimated $201K sold.

Doliver Advisors first reported a position in CRSP in Q1 2021 and held it in 7 quarters. The position peaked at $452K in Q2 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Doliver Advisors reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Doliver Advisors sold 3,083 CRISPR Therapeutics shares in Q4 2022, an estimated $201K.
  • Doliver Advisors first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 7 quarters.
  • Doliver Advisors's CRISPR Therapeutics position peaked at $452K in Q2 2021.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Doliver Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.